In an interview with PharmaShots, Alyssa Johnsen, MD, Ph.D., Vice President, Rheumatology and Maternal-Fetal Health Disease Area Leader at Janssen Research & Development shares her views on the P-III DISCOVER-1 & 2 Studies of Tremfya (guselkumab) for the treatment of psoriatic arthritis in ACR 2021 and published in Arthritis & Rheumatology
Shots:
The P-III DISCOVER-1 & 2 trials evaluate Tremfya (SC) vs PBO in 381 & 739…
In an interview with PharmaShots, Dr. Amit Etkin, CEO and Founder of Alto Neuroscience shared his views on its clinical stage pipeline in the emerging hot precision psychiatry space. He also put his views on the funding received by the company for the development of its pipeline.
Shots:
Using precision psychiatry, the company’s human data R&D platform identifies brain biomarkers…
In an interview with PharmaShots, Joe Eazor, CEO at Clario share his views on the ERT’s merger with Bioclinica to become Clario for clinical trial innovation and evidence
ERT & Bioclinica merged to become Clario, following its Apr 2021 merger agreement & to generate the clinical evidence, empower the patients & transform their lives by providing better evidence
Clario combines Bioclinica's expertise in imaging,…
In an interview with PharmaShots, Shannon Burke, Synchrony Senior Vice President, and General Manager, Health Systems, share her views on healthcare financing & empowers the patients to pay for their healthcare
Synchrony’s CareCredit card is a comprehensive healthcare financial solution that is designed for health and wellness needs. The CareCredit solution helps health systems, reduce accounts receivable, increase revenue,…
In an interview with PharmaShots, Andrew Hall, CEO at IMV share his views on the data of DPX delivery platform in the bladder and ovarian cancer, presented in two e-posters at the AACR-NCI-EORTC virtual conference
Shots:
The company has reported additional data to support the immunotherapeutic capabilities of its DPX technology. In pre-clinical/clinical data, DPX technology generates peptide-specific, T cell-based immune…
In an interview with PharmaShots, Matt Walz, CEO at Trialbee share his views on the launch of the Trialbee Honey platform to empower patient recruitment
Shots:
Trialbee launched Trialbee Honey that allows to track, measure, and analyze all patient enrollment activities in clinical trials
The platform is designed to address clinical research and trial barriers by using data to optimize the patient experience,…
In an interview with PharmaShots, Anthony Ho, Global Head of Strategic Planning for Molecular Diagnostics at QIAGEN share his views on the winner of the $3.4M US DOD contract to increase the production of COVID-19 PCR test
Shots:
QIAGEN has received a $3.4M contract from the US DOD in coordination with the Department of HHS to increase the production capacity for…
In an interview with PharmaShots, Meghan Scanlon, Senior Vice President and President for Urology and Pelvic Health at Boston Scientific shares her views on the completion of its $1.07B acquisition of Lumenis surgical business
Shots:
Boston Scientific reported the closing of its acquisition of the Lumenis surgical business from a BPEA affiliate for an upfront of $1.07B. The acquisition follows the Mar…
In an interview with PharmaShots, Thierry Abribat, Founder and Chief Executive Officer at Amolyt Pharma shares his views on the data from the P-I trial of AZP-3601 for the treatment of Hypoparathyroidism
Shots:
The P-I trial evaluates the safety, tolerability, PK, PD, and preliminary efficacy of AZP-3601 in 102 healthy volunteers including 52 in the SAD and 50 in the MAD cohorts…
In an interview with PharmaShots, Alexander Bedenkov, Vice President, Medical International Region & Global Health Innovation Hubs (A.Catalyst) Network Head at AstraZeneca shares his views on the First Virtual Events in collaboration with Slush to accelerate better health outcomes through innovation
Shots:
The companies collaborated to launch virtual events and enhance collaboration in the healthcare sector. The event was run through AstraZeneca’s A.Catalyst Network,…

